Premium
Persistence with Estrogen Therapy in a Postmenopausal Medicaid Population
Author(s) -
Kotzan Jeffrey A.,
Martin Bradley C.,
Wade William E.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.4.363.30935
Subject(s) - discontinuation , persistence (discontinuity) , medicine , demography , medicaid , estrogen therapy , population , survival analysis , estrogen , environmental health , sociology , engineering , economics , health care , geotechnical engineering , economic growth
We evaluated rates of persistence with estrogen replacement therapy in postmenopausal Georgia Medicaid recipients adjusted for age and race. Data files for 1992–1994 were examined to estimate 3‐year conditional survival probabilities using the Kaplan‐Meier model, and 3800 subjects were identified. Over 54% of women remained compliant over 29 months, and 17% continued therapy for the entire 35 months of observation. Kaplan‐Meier predictors indicated that white women have a 70% chance of being compliant for 3 years, whereas black women have a 60% chance. Monthly discontinuation rates ranged from 1–1.5% after the second month of therapy. Younger, white women were the most likely to maintain and comply with therapy.